Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

2023231 citationsJournal Article

Authors

Good health and well-being

Published in: Nature Medicine

Volume 29, Issue 2, pp. 422-429

Field-Weighted Citation Impact: 52.71